340B policy is moving across payment, purchasing and data requirements, while covered entities contest how program savings are handled. On November 4, CMS finalized its 2027 outpatient rule, raising qualifying hospitals’ outpatient payment rates by 2.3% while cutting payment for 340B-acquired drugs. The University of Kentucky and Ashland Hospital Corporation sued CVS Health and affiliates on October 27, alleging diversion of more than $41 million in 340B savings. Five Massachusetts hospitals sued Lilly the same day, alleging it unlawfully ended 340B discounts after they refused to provide patient claims data. Separately, HRSA approved rebate pilot plans covering 21 drugs from 10 manufacturers, requiring full-price purchases before rebates beginning January 1 unless a court or Congress stops the change. Together, these developments put payment levels, control over savings and access to claims data at issue, as hospitals challenge CVS and Lilly and the rebate pilot creates a new purchasing sequence for covered entities.
CMS finalized the rule November 4, raising qualifying hospitals’ outpatient payment rates 2.3% while cutting payment for 340B-acquired drugs.
The university and Ashland Hospital Corporation sued CVS Health and affiliates October 27 over alleged diversion of 340B savings.
The hospitals sued October 27, alleging Lilly unlawfully cut off 340B discounts after they refused to provide patient claims data.
HRSA approved plans that would require full-price purchases before rebates beginning January 1, unless a court or Congress stops the change.
Attorney General Catherine Hanaway’s October 26 cease-and-desist letter asked Lilly to end its claims-data policy by November 26.
Its October 8 report found inflation-adjusted payments for 340B drugs furnished by non-exempt providers rose from $7.1 billion to $10.7 billion during 2021-2023.
AJMC reports most CAA 2026 PBM provisions take effect for plan years beginning on or after August 3, 2028, or January 1, 2029, for calendar-year plans.
- Becker’s reports that the January 1 pilot would require hospitals to pay full price for 21 drugs before receiving 340B rebates.
- Five Massachusetts hospitals allege Lilly cut off discounts after they refused patient claims-data demands; their October 27 lawsuit remains an active dispute.
- The University of Kentucky and Ashland Hospital Corporation allege CVS companies diverted more than $41 million in 340B savings.
- CMS finalized lower payment for 340B-acquired drugs on November 4, but the supplied report does not specify the final payment formula.
- HRSA requires manufacturers to make quarterly ceiling-price files available by 11-digit NDC for Medicaid billing, sliding-fee calculations or patient cost sharing.
- HRSA specifies unit-level rebates rather than accumulation of a full package, giving covered entities a stated basis for rebate reconciliation.
- The PROTECT 340B Act would prohibit lower reimbursement, extra fees and contract-pharmacy network exclusions based on 340B participation.
- AJMC reports a November 23 response deadline for CMS’s request for information on pharmacy reimbursement terms in PBM contracts.
- Separate the November 4 final-rule payment cut from ASPE’s October 8 discussion of the proposed ASP-minus-33.4% formula.
- Use HRSA’s dispense-date ceiling price and unit-level methodology when reviewing rebate reconciliation requirements.
- Track January 1 negotiated-price changes alongside the pilot’s planned transition for drugs subject to both changes.
- Monitor Lilly’s response to Missouri Attorney General Catherine Hanaway’s November 26 deadline to end its claims-data policy.
- CMS finalized its 2027 hospital outpatient and ASC payment rule November 4.
- Outpatient payment rates rise 2.3% for hospitals that meet quality reporting requirements.
- The increase combines a 3.2% market basket update and a 0.9-percentage-point productivity adjustment.
- The rule cuts payment for 340B-acquired drugs and expands site-neutral payments to imaging.
- CMS continues to phase out the inpatient-only list.
- The University of Kentucky and Ashland Hospital Corporation sued CVS Health and affiliates October 27.
- The plaintiffs allege the companies diverted more than $41 million in 340B savings from the health system.
- The complaint names CVS Health, CaremarkPCS Health, Caremark d/b/a CVS Specialty and WellPartner.
- The plaintiffs filed in the U.S. District Court for the Eastern District of Kentucky.
- Ashland Hospital Corporation operates UK King’s Daughters Medical Center.
- Five Massachusetts hospitals sued Eli Lilly October 27 in the U.S. District Court for the District of Massachusetts.
- The hospitals allege Lilly unlawfully cut off their 340B discounts after they refused to provide patient claims data.
- The complaint alleges violations of Massachusetts’ consumer protection law and unjust enrichment.
- Plaintiffs include Massachusetts General Hospital, Brigham and Women’s Hospital and North Shore Medical Center (Salem Hospital).
- UMass Memorial Medical Center and UMass Memorial Health-Harrington Hospital also joined the suit.
- Reps. Doris Matsui and Tracey Mann introduced the bipartisan PROTECT 340B Act October 29.
- The bill would prohibit lower reimbursement for 340B drugs and extra fees on covered entities and their contract pharmacies.
- The bill would prohibit contract-pharmacy network exclusions and other discriminatory conditions based on program participation.
- The Association of American Medical Colleges and other hospital groups endorsed the bill.
- The American Hospital Association requested revisions to the SUSTAIN 340B Act in an October 27 letter to its six Senate sponsors.
- The AHA supports provisions to codify contract-pharmacy use and establish a data clearinghouse.
- The six senators introduced the bill August 5.
- Sponsors include Jerry Moran, Tammy Baldwin, Shelley Moore Capito, Tim Kaine, John Boozman and John Hickenlooper.
- HRSA approved rebate plans from 10 manufacturers covering 21 drugs for its revised pilot.
- Hospitals would pay full price upfront and receive their 340B discounts later as rebates.
- The change is scheduled for January 1 unless a court or Congress stops it.
- Covered entities would continue purchasing through their 340B wholesaler accounts.
- Participating manufacturers include AbbVie, Amgen, Astellas, AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, GSK, Merck, Pfizer and Teva.
| Court | Matter | Date |
|---|---|---|
| U.S. District Court for the Eastern District of Kentucky | University of Kentucky sues CVS over alleged $41M 340B scheme; the university and Ashland Hospital Corporation filed October 27. The supplied item does not print a formal case caption or docket number. [source] | 2026-10-30 |
| U.S. District Court for the District of Massachusetts | 5 Massachusetts hospitals sue Eli Lilly over 340B data demands; the hospitals filed October 27. The supplied item does not print a formal case caption or docket number. [source] | 2026-10-27 |
| Manufacturer | Action | Date |
|---|---|---|
| Eli Lilly | Five Massachusetts hospitals alleged October 27 that Lilly cut off 340B discounts after they refused to provide patient claims data. [source] | 2026-10-27 |
| Amgen | HRSA approved a rebate plan within the 10-manufacturer, 21-drug pilot scheduled for January 1. [source] | 2026-10-26 |
| Astellas | HRSA approved a rebate plan within the 10-manufacturer, 21-drug pilot scheduled for January 1. [source] | 2026-10-26 |
| AstraZeneca | HRSA approved a rebate plan within the 10-manufacturer, 21-drug pilot scheduled for January 1. [source] | 2026-10-26 |
| Bristol Myers Squibb | HRSA approved a rebate plan within the 10-manufacturer, 21-drug pilot scheduled for January 1. [source] | 2026-10-26 |
| Boehringer Ingelheim | HRSA approved a rebate plan within the 10-manufacturer, 21-drug pilot scheduled for January 1. [source] | 2026-10-26 |
| GSK | HRSA approved a rebate plan within the 10-manufacturer, 21-drug pilot scheduled for January 1. [source] | 2026-10-26 |
| Merck | HRSA approved a rebate plan within the 10-manufacturer, 21-drug pilot scheduled for January 1. [source] | 2026-10-26 |
| Pfizer | HRSA approved a rebate plan within the 10-manufacturer, 21-drug pilot scheduled for January 1. [source] | 2026-10-26 |
| Teva | HRSA approved a rebate plan within the 10-manufacturer, 21-drug pilot scheduled for January 1. [source] | 2026-10-26 |
The review screened material dated August 7 through November 5, 2026, and retained distinct, directly accessible statements, named commentary, and public social discussion; it excluded duplicate and undated material.
- Main theme: Jordan Valley Health CEO Matthew Stinson supports reform goals but calls for safeguards against rebate delays, disputed claims, and added health-center costs.
- Stakeholder sentiment: Health-center provider view: concerned but open to reform. Stinson writes, “FQHCs do not oppose reform.”
- Potential implications: His proposed safeguards include timely payment enforcement, common data rules, and protections for health centers with limited cash reserves.
- Credibility: A first-person policy essay by a named FQHC leader; it is useful for the provider’s position, not independent evidence of program effects.
- Main theme: Gaby Hartney compares rebate and clearinghouse models as ways to improve transaction checks, while noting possible cash-flow strain for providers.
- Stakeholder sentiment: Policy-commentary view: supportive of stronger transaction oversight, with caution about effects on rural and smaller providers. Hartney writes, “The two models have tradeoffs.”
- Potential implications: The memo puts provider liquidity alongside transaction-level accountability in the debate over program changes.
- Credibility: A dated policy memo by a named Third Way author that cites outside sources; it is advocacy analysis, not peer-reviewed research.
- Main theme: Commenters discuss hospital pharmacy finances, with one linking 340B to pharmacy margins and the forthcoming rebate proposal.
- Stakeholder sentiment: Anonymous pharmacy-worker discussion: concerned about the rebate proposal’s financial effect. One commenter wrote, “With 340b it’s about to be a loss starting 2027 with the new proposal of reimbursement.”
- Potential implications: The thread signals concern among some pharmacy participants about whether hospitals can sustain current pharmacy operations under the proposal.
- Credibility: Public user-generated discussion with no verified identities; it shows individual sentiment and is not representative evidence.
- November 23: AJMC reports that responses are due to CMS’s request for information on pharmacy reimbursement terms in PBM contracts. [source]
- November 26: Missouri Attorney General Catherine Hanaway asked Lilly to end its claims-data policy by this date. [source]
- January 1: The 21-drug rebate pilot is scheduled to begin unless a court or Congress stops the change. [source]
- January 1: Medicare negotiated prices take effect for 15 more drugs, several of which also face rebate-only 340B pricing. [source]
- 2027: CMS’s finalized outpatient rule raises qualifying hospitals’ payment rates 2.3% and cuts payment for 340B-acquired drugs. [source]
This briefing is provided for informational purposes only and does not constitute legal, regulatory, financial, or compliance advice. Automated summarization may contain errors or omissions, and source materials may change after publication. Recipients should independently verify all information against the cited primary sources before relying on it.
© 2026 MedMatrix Rx. All rights reserved.